In defense of Phase I trials

Hematol J. 2000;1(6):427. doi: 10.1038/sj.thj.6200069.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials, Phase I as Topic*
  • Ethics, Medical
  • Humans
  • Maximum Tolerated Dose
  • Neoplasms / drug therapy
  • Practice Guidelines as Topic

Substances

  • Antineoplastic Agents